Kazumasa Wakamatsu Selected Research

4-S-cysteaminylphenol

3/2007	4-S-Cysteaminylphenol-loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma.
4/2004	Comparison of in vivo anti-melanoma effect of enantiomeric alpha-methyl- and alpha-ethyl-4-S-cysteaminylphenol.
12/2003	Synthesis and selective in vitro anti-melanoma effect of enantiomeric alpha-methyl- and alpha-ethyl-4-S-cysteaminylphenol.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazumasa Wakamatsu Research Topics

Disease

40	Melanoma (Melanoma, Malignant) 06/2022 - 12/2002
16	Neoplasms (Cancer) 06/2022 - 08/2004
8	Parkinson Disease (Parkinson's Disease) 04/2022 - 08/2003
8	Skin Neoplasms (Skin Cancer) 11/2018 - 06/2002
6	Experimental Melanoma 01/2017 - 12/2002
5	Neoplasm Metastasis (Metastasis) 01/2020 - 08/2003
5	Hyperpigmentation 04/2019 - 02/2003
5	Sunburn 01/2017 - 10/2004
4	Carcinogenesis 01/2017 - 12/2009
4	Hyperthermia 06/2013 - 03/2007
2	Obesity 01/2022 - 12/2008
2	Hypopigmentation (Hypomelanosis) 01/2022 - 01/2019
2	Genomic Instability 01/2021 - 10/2010
2	Wounds and Injuries (Trauma) 10/2020 - 02/2007
2	Phototoxic Dermatitis (Phototoxicity) 05/2020 - 07/2010
2	Albinism 01/2019 - 11/2018
2	Oculocutaneous Albinism (Albinism, Yellow Mutant) 01/2019 - 01/2018
2	Vitiligo 11/2018 - 05/2011
2	Lymphoma (Lymphomas) 04/2015 - 09/2009
2	Melanosis (Freckles) 07/2012 - 09/2004
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2009 - 01/2007
2	Pigmented Nevus (Melanocytic Nevus) 11/2005 - 10/2004
1	Movement Disorders (Movement Disorder) 04/2022
1	Hyperphagia (Overeating) 01/2022
1	Atopic Dermatitis (Atopic Eczema) 01/2021
1	Hyperplasia 01/2021
1	Infections 10/2020
1	Inflammation (Inflammations) 01/2020
1	Eye Abnormalities (Eye Abnormality) 01/2019
1	Oculocutaneous albinism type 2 11/2018
1	Hermanski-Pudlak Syndrome (Hermansky-Pudlak Syndrome) 01/2018
1	Nevus (Nevi) 01/2018
1	Alopecia Areata 01/2018
1	Hemorrhage 01/2018

Drug/Important Bio-Agent (IBA)

30	Melanins (Melanin)IBA 06/2022 - 08/2003
14	pheomelaninIBA 01/2018 - 12/2002
13	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2004
10	eumelaninIBA 01/2020 - 10/2004
9	Monophenol Monooxygenase (Tyrosinase)IBA 04/2022 - 04/2004
6	Reactive Oxygen Species (Oxygen Radicals)IBA 06/2022 - 09/2005
6	Biomarkers (Surrogate Marker)IBA 01/2020 - 08/2003
5	Biological ProductsIBA 06/2022 - 10/2003
5	Free RadicalsIBA 06/2022 - 06/2005
5	CysteinyldopaIBA 01/2020 - 08/2003
5	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 06/2002
4	Dopamine (Intropin)FDA LinkGeneric 04/2022 - 01/2007
4	Type 1 Melanocortin ReceptorIBA 01/2020 - 08/2006
4	Cysteine (L-Cysteine)FDA Link 01/2017 - 12/2002
4	Pyrimidine DimersIBA 04/2015 - 10/2004
4	Tyrosine (L-Tyrosine)FDA Link 01/2013 - 03/2007
4	N-propionyl-4-S-cysteaminylphenolIBA 01/2013 - 09/2010
4	AminesIBA 01/2013 - 12/2003
3	AntioxidantsIBA 06/2022 - 07/2012
3	neuromelaninIBA 04/2022 - 08/2003
3	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 01/2022 - 12/2008
3	ColforsinIBA 01/2020 - 04/2009
3	SulfurIBA 01/2013 - 03/2007
3	Caspase 3 (Caspase-3)IBA 07/2012 - 10/2004
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 07/2012 - 05/2011
3	Ferrosoferric Oxide (Magnetite)FDA Link 09/2009 - 03/2007
3	4-S-cysteaminylphenolIBA 03/2007 - 12/2003
3	4-amino-3-hydroxyphenylalanineIBA 04/2006 - 08/2003
2	EnzymesIBA 06/2022 - 03/2014
2	Melanocyte-Stimulating Hormones (MSH)IBA 01/2022 - 01/2017
2	Microphthalmia-Associated Transcription FactorIBA 01/2021 - 07/2012
2	NivolumabIBA 01/2019 - 11/2018
2	quinone (benzoquinone)IBA 01/2017 - 09/2012
2	rhododendrolIBA 01/2017 - 05/2015
2	Sulfhydryl Compounds (Thiols)IBA 01/2017 - 05/2015
2	Messenger RNA (mRNA)IBA 04/2015 - 10/2004
2	aloe emodinIBA 01/2015 - 01/2014
2	Dextrans (Dextran)FDA Link 03/2014 - 01/2014
2	Peptides (Polypeptides)IBA 01/2013 - 09/2010
2	Glutathione (Reduced Glutathione)IBA 07/2012 - 12/2002
2	MelanocortinsIBA 10/2010 - 09/2006
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 09/2010 - 01/2009
2	GlypicansIBA 11/2005 - 10/2004
2	Tumor Biomarkers (Tumor Markers)IBA 11/2005 - 10/2004
2	alpha-MSHIBA 02/2003 - 06/2002
1	Pharmaceutical PreparationsIBA 06/2022
1	Neurotransmitter Agents (Neurotransmitter)IBA 04/2022
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 04/2022
1	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2022
1	Monoamine Oxidase (MAO)IBA 10/2021
1	AldehydesIBA 10/2021
1	catechol (pyrocatechol)IBA 10/2021
1	3,4-dihydroxyphenylacetaldehydeIBA 10/2021
1	Singlet OxygenIBA 04/2021
1	Aldehyde DehydrogenaseIBA 04/2019
1	Ethanol (Ethyl Alcohol)IBA 04/2019
1	nitisinone (Orfadin)FDA Link 01/2019
1	pembrolizumabIBA 01/2019
1	CeroidIBA 01/2018
1	benzothiazoleIBA 01/2018

Therapy/Procedure

8	Therapeutics 06/2022 - 03/2007
5	Immunotherapy 06/2022 - 01/2009
3	Drug Therapy (Chemotherapy) 06/2022 - 09/2006
2	Injections 09/2012 - 07/2012
2	Renal Dialysis (Hemodialysis) 01/2009 - 01/2007
1	Immunomodulation 06/2022